nodes	percent_of_prediction	percent_of_DWPC	metapath
Amprenavir—CYP3A5—prostate cancer	0.147	0.473	CbGaD
Amprenavir—CYP2C19—prostate cancer	0.0999	0.322	CbGaD
Amprenavir—CYP3A4—prostate cancer	0.0635	0.205	CbGaD
Amprenavir—ABCC1—Abiraterone—prostate cancer	0.0402	0.0817	CbGbCtD
Amprenavir—ABCC1—Conjugated Estrogens—prostate cancer	0.019	0.0386	CbGbCtD
Amprenavir—CYP2C8—Nilutamide—prostate cancer	0.0173	0.0351	CbGbCtD
Amprenavir—ABCC1—Mitoxantrone—prostate cancer	0.0173	0.0351	CbGbCtD
Amprenavir—CYP3A5—Flutamide—prostate cancer	0.0149	0.0303	CbGbCtD
Amprenavir—CYP2C19—Bicalutamide—prostate cancer	0.0145	0.0295	CbGbCtD
Amprenavir—CYP2C19—Nilutamide—prostate cancer	0.0145	0.0295	CbGbCtD
Amprenavir—CYP2C8—Abiraterone—prostate cancer	0.0143	0.0291	CbGbCtD
Amprenavir—ABCC1—Epirubicin—prostate cancer	0.014	0.0284	CbGbCtD
Amprenavir—CYP2B6—Estrone—prostate cancer	0.0137	0.0278	CbGbCtD
Amprenavir—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0134	0.0271	CbGbCtD
Amprenavir—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0122	0.0248	CbGbCtD
Amprenavir—CYP2C9—Bicalutamide—prostate cancer	0.0121	0.0245	CbGbCtD
Amprenavir—CYP2C9—Nilutamide—prostate cancer	0.0121	0.0245	CbGbCtD
Amprenavir—CYP2C19—Flutamide—prostate cancer	0.012	0.0244	CbGbCtD
Amprenavir—CYP2D6—Bicalutamide—prostate cancer	0.011	0.0224	CbGbCtD
Amprenavir—CYP3A5—Cabazitaxel—prostate cancer	0.011	0.0224	CbGbCtD
Amprenavir—ABCC1—Etoposide—prostate cancer	0.0109	0.0221	CbGbCtD
Amprenavir—ABCB1—Estramustine—prostate cancer	0.0109	0.0221	CbGbCtD
Amprenavir—CYP3A5—Estrone—prostate cancer	0.0108	0.0219	CbGbCtD
Amprenavir—CYP2C8—Cabazitaxel—prostate cancer	0.0106	0.0215	CbGbCtD
Amprenavir—ABCC1—Docetaxel—prostate cancer	0.00997	0.0203	CbGbCtD
Amprenavir—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00923	0.0188	CbGbCtD
Amprenavir—CYP2D6—Abiraterone—prostate cancer	0.00914	0.0186	CbGbCtD
Amprenavir—ABCC1—Doxorubicin—prostate cancer	0.00743	0.0151	CbGbCtD
Amprenavir—CYP2C9—Estrone—prostate cancer	0.00723	0.0147	CbGbCtD
Amprenavir—ABCB1—Cabazitaxel—prostate cancer	0.00718	0.0146	CbGbCtD
Amprenavir—CYP3A4—Bicalutamide—prostate cancer	0.00701	0.0143	CbGbCtD
Amprenavir—ABCB1—Estrone—prostate cancer	0.00701	0.0142	CbGbCtD
Amprenavir—CYP3A4—Estramustine—prostate cancer	0.00652	0.0132	CbGbCtD
Amprenavir—ABCB1—Ethinyl Estradiol—prostate cancer	0.00625	0.0127	CbGbCtD
Amprenavir—CYP3A5—Estradiol—prostate cancer	0.00619	0.0126	CbGbCtD
Amprenavir—CYP2C8—Estradiol—prostate cancer	0.00595	0.0121	CbGbCtD
Amprenavir—CYP3A4—Abiraterone—prostate cancer	0.00581	0.0118	CbGbCtD
Amprenavir—CYP3A4—Flutamide—prostate cancer	0.00581	0.0118	CbGbCtD
Amprenavir—CYP2C9—Capecitabine—prostate cancer	0.00548	0.0111	CbGbCtD
Amprenavir—CYP2C19—Estradiol—prostate cancer	0.00499	0.0101	CbGbCtD
Amprenavir—ABCB1—Conjugated Estrogens—prostate cancer	0.00459	0.00932	CbGbCtD
Amprenavir—CYP3A4—Cabazitaxel—prostate cancer	0.0043	0.00873	CbGbCtD
Amprenavir—CYP2C19—Prednisone—prostate cancer	0.00429	0.00872	CbGbCtD
Amprenavir—CYP3A4—Estrone—prostate cancer	0.0042	0.00854	CbGbCtD
Amprenavir—ABCB1—Mitoxantrone—prostate cancer	0.00417	0.00847	CbGbCtD
Amprenavir—CYP2C9—Estradiol—prostate cancer	0.00415	0.00843	CbGbCtD
Amprenavir—CYP3A5—Etoposide—prostate cancer	0.00404	0.00821	CbGbCtD
Amprenavir—ABCB1—Estradiol—prostate cancer	0.00403	0.00818	CbGbCtD
Amprenavir—CYP2C8—Etoposide—prostate cancer	0.00389	0.00789	CbGbCtD
Amprenavir—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00375	0.00761	CbGbCtD
Amprenavir—CYP3A5—Docetaxel—prostate cancer	0.0037	0.00751	CbGbCtD
Amprenavir—CYP2B6—Doxorubicin—prostate cancer	0.0035	0.00711	CbGbCtD
Amprenavir—ABCB1—Prednisone—prostate cancer	0.00346	0.00704	CbGbCtD
Amprenavir—CYP3A4—Conjugated Estrogens—prostate cancer	0.00275	0.00559	CbGbCtD
Amprenavir—ABCB1—Etoposide—prostate cancer	0.00263	0.00534	CbGbCtD
Amprenavir—CYP3A4—Mitoxantrone—prostate cancer	0.0025	0.00508	CbGbCtD
Amprenavir—CYP3A4—Estradiol—prostate cancer	0.00241	0.0049	CbGbCtD
Amprenavir—ABCB1—Docetaxel—prostate cancer	0.00241	0.00489	CbGbCtD
Amprenavir—CYP3A4—Prednisone—prostate cancer	0.00208	0.00422	CbGbCtD
Amprenavir—ABCB1—Doxorubicin—prostate cancer	0.00179	0.00364	CbGbCtD
Amprenavir—CYP2D6—Doxorubicin—prostate cancer	0.00169	0.00343	CbGbCtD
Amprenavir—CYP3A4—Etoposide—prostate cancer	0.00158	0.0032	CbGbCtD
Amprenavir—CYP3A4—Docetaxel—prostate cancer	0.00144	0.00293	CbGbCtD
Amprenavir—CYP2C19—urine—prostate cancer	0.00129	0.155	CbGeAlD
Amprenavir—CYP3A4—Doxorubicin—prostate cancer	0.00107	0.00218	CbGbCtD
Amprenavir—CYP2C9—urine—prostate cancer	0.001	0.12	CbGeAlD
Amprenavir—Darunavir—CYP3A4—prostate cancer	0.000914	0.5	CrCbGaD
Amprenavir—Fosamprenavir—CYP3A4—prostate cancer	0.000914	0.5	CrCbGaD
Amprenavir—CYP3A4—urine—prostate cancer	0.000764	0.0916	CbGeAlD
Amprenavir—CYP2D6—urine—prostate cancer	0.000751	0.0901	CbGeAlD
Amprenavir—ABCC1—prostate gland—prostate cancer	0.000475	0.057	CbGeAlD
Amprenavir—ABCC1—seminal vesicle—prostate cancer	0.000402	0.0482	CbGeAlD
Amprenavir—CYP3A5—prostate gland—prostate cancer	0.000365	0.0438	CbGeAlD
Amprenavir—ABCC1—urethra—prostate cancer	0.000318	0.0382	CbGeAlD
Amprenavir—CYP2C8—renal system—prostate cancer	0.000276	0.0331	CbGeAlD
Amprenavir—CYP3A5—renal system—prostate cancer	0.000249	0.0298	CbGeAlD
Amprenavir—CYP2B6—renal system—prostate cancer	0.000247	0.0297	CbGeAlD
Amprenavir—ABCC1—testis—prostate cancer	0.000209	0.0251	CbGeAlD
Amprenavir—ABCB1—prostate gland—prostate cancer	0.000194	0.0233	CbGeAlD
Amprenavir—CYP3A4—renal system—prostate cancer	0.000187	0.0224	CbGeAlD
Amprenavir—CYP2D6—renal system—prostate cancer	0.000184	0.022	CbGeAlD
Amprenavir—CYP2C8—testis—prostate cancer	0.000178	0.0214	CbGeAlD
Amprenavir—ABCB1—seminal vesicle—prostate cancer	0.000164	0.0197	CbGeAlD
Amprenavir—CYP2B6—testis—prostate cancer	0.00016	0.0192	CbGeAlD
Amprenavir—ABCC1—lymph node—prostate cancer	0.000152	0.0182	CbGeAlD
Amprenavir—ABCB1—epithelium—prostate cancer	0.000143	0.0171	CbGeAlD
Amprenavir—ABCB1—renal system—prostate cancer	0.000132	0.0159	CbGeAlD
Amprenavir—ABCB1—urethra—prostate cancer	0.00013	0.0156	CbGeAlD
Amprenavir—CYP2D6—testis—prostate cancer	0.000119	0.0142	CbGeAlD
Amprenavir—Nausea—Bicalutamide—prostate cancer	0.000111	0.00106	CcSEcCtD
Amprenavir—Neutropenia—Docetaxel—prostate cancer	0.000109	0.00104	CcSEcCtD
Amprenavir—Abdominal discomfort—Capecitabine—prostate cancer	0.000108	0.00103	CcSEcCtD
Amprenavir—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000108	0.00103	CcSEcCtD
Amprenavir—Myalgia—Estradiol—prostate cancer	0.000107	0.00103	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000106	0.00102	CcSEcCtD
Amprenavir—Gastrointestinal pain—Goserelin—prostate cancer	0.000106	0.00101	CcSEcCtD
Amprenavir—Erythema multiforme—Etoposide—prostate cancer	0.000106	0.00101	CcSEcCtD
Amprenavir—Discomfort—Estradiol—prostate cancer	0.000106	0.00101	CcSEcCtD
Amprenavir—Neutropenia—Capecitabine—prostate cancer	0.000105	0.00101	CcSEcCtD
Amprenavir—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000105	0.001	CcSEcCtD
Amprenavir—Diabetes mellitus—Epirubicin—prostate cancer	0.000104	0.000999	CcSEcCtD
Amprenavir—Cardiac disorder—Etoposide—prostate cancer	0.000104	0.000995	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000103	0.000984	CcSEcCtD
Amprenavir—Abdominal pain—Goserelin—prostate cancer	0.000102	0.00098	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Prednisone—prostate cancer	0.000102	0.00098	CcSEcCtD
Amprenavir—Acute coronary syndrome—Docetaxel—prostate cancer	0.000102	0.000978	CcSEcCtD
Amprenavir—Myocardial infarction—Docetaxel—prostate cancer	0.000102	0.000973	CcSEcCtD
Amprenavir—Hyperglycaemia—Capecitabine—prostate cancer	0.000102	0.000972	CcSEcCtD
Amprenavir—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000102	0.000971	CcSEcCtD
Amprenavir—Nervous system disorder—Estradiol—prostate cancer	0.000101	0.000964	CcSEcCtD
Amprenavir—Depression—Capecitabine—prostate cancer	0.0001	0.000958	CcSEcCtD
Amprenavir—Vomiting—Ethinyl Estradiol—prostate cancer	0.0001	0.000958	CcSEcCtD
Amprenavir—ABCB1—bone marrow—prostate cancer	0.0001	0.012	CbGeAlD
Amprenavir—Myalgia—Mitoxantrone—prostate cancer	9.99e-05	0.000955	CcSEcCtD
Amprenavir—Skin disorder—Estradiol—prostate cancer	9.98e-05	0.000954	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Capecitabine—prostate cancer	9.96e-05	0.000953	CcSEcCtD
Amprenavir—Rash—Ethinyl Estradiol—prostate cancer	9.93e-05	0.00095	CcSEcCtD
Amprenavir—Dermatitis—Ethinyl Estradiol—prostate cancer	9.92e-05	0.000949	CcSEcCtD
Amprenavir—Acute coronary syndrome—Capecitabine—prostate cancer	9.91e-05	0.000947	CcSEcCtD
Amprenavir—Discomfort—Mitoxantrone—prostate cancer	9.87e-05	0.000944	CcSEcCtD
Amprenavir—Headache—Ethinyl Estradiol—prostate cancer	9.87e-05	0.000944	CcSEcCtD
Amprenavir—Myocardial infarction—Capecitabine—prostate cancer	9.85e-05	0.000942	CcSEcCtD
Amprenavir—Hepatobiliary disease—Docetaxel—prostate cancer	9.82e-05	0.000939	CcSEcCtD
Amprenavir—Diabetes mellitus—Doxorubicin—prostate cancer	9.66e-05	0.000924	CcSEcCtD
Amprenavir—Hepatobiliary disease—Capecitabine—prostate cancer	9.5e-05	0.000909	CcSEcCtD
Amprenavir—Neutropenia—Prednisone—prostate cancer	9.39e-05	0.000898	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Estradiol—prostate cancer	9.36e-05	0.000895	CcSEcCtD
Amprenavir—Nausea—Ethinyl Estradiol—prostate cancer	9.36e-05	0.000895	CcSEcCtD
Amprenavir—Asthenia—Goserelin—prostate cancer	9.3e-05	0.000889	CcSEcCtD
Amprenavir—Skin disorder—Mitoxantrone—prostate cancer	9.3e-05	0.000889	CcSEcCtD
Amprenavir—Paraesthesia—Estradiol—prostate cancer	9.23e-05	0.000882	CcSEcCtD
Amprenavir—Asthenia—Conjugated Estrogens—prostate cancer	9.21e-05	0.000881	CcSEcCtD
Amprenavir—Pruritus—Goserelin—prostate cancer	9.17e-05	0.000877	CcSEcCtD
Amprenavir—Connective tissue disorder—Docetaxel—prostate cancer	9.16e-05	0.000875	CcSEcCtD
Amprenavir—Anorexia—Mitoxantrone—prostate cancer	9.13e-05	0.000873	CcSEcCtD
Amprenavir—Pruritus—Conjugated Estrogens—prostate cancer	9.09e-05	0.000869	CcSEcCtD
Amprenavir—Hyperglycaemia—Prednisone—prostate cancer	9.06e-05	0.000866	CcSEcCtD
Amprenavir—Decreased appetite—Estradiol—prostate cancer	8.93e-05	0.000854	CcSEcCtD
Amprenavir—Depression—Prednisone—prostate cancer	8.93e-05	0.000853	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Estradiol—prostate cancer	8.87e-05	0.000848	CcSEcCtD
Amprenavir—Diarrhoea—Goserelin—prostate cancer	8.87e-05	0.000848	CcSEcCtD
Amprenavir—Connective tissue disorder—Capecitabine—prostate cancer	8.87e-05	0.000848	CcSEcCtD
Amprenavir—Fatigue—Estradiol—prostate cancer	8.86e-05	0.000847	CcSEcCtD
Amprenavir—Acute coronary syndrome—Prednisone—prostate cancer	8.82e-05	0.000844	CcSEcCtD
Amprenavir—Erythema multiforme—Docetaxel—prostate cancer	8.81e-05	0.000842	CcSEcCtD
Amprenavir—Diarrhoea—Conjugated Estrogens—prostate cancer	8.79e-05	0.00084	CcSEcCtD
Amprenavir—Myocardial infarction—Prednisone—prostate cancer	8.77e-05	0.000839	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	8.72e-05	0.000834	CcSEcCtD
Amprenavir—Cardiac disorder—Docetaxel—prostate cancer	8.65e-05	0.000827	CcSEcCtD
Amprenavir—Paraesthesia—Mitoxantrone—prostate cancer	8.6e-05	0.000822	CcSEcCtD
Amprenavir—ABCB1—testis—prostate cancer	8.55e-05	0.0102	CbGeAlD
Amprenavir—Erythema multiforme—Capecitabine—prostate cancer	8.53e-05	0.000816	CcSEcCtD
Amprenavir—Gastrointestinal pain—Estradiol—prostate cancer	8.4e-05	0.000804	CcSEcCtD
Amprenavir—Liver function test abnormal—Epirubicin—prostate cancer	8.39e-05	0.000802	CcSEcCtD
Amprenavir—Cardiac disorder—Capecitabine—prostate cancer	8.37e-05	0.0008	CcSEcCtD
Amprenavir—Decreased appetite—Mitoxantrone—prostate cancer	8.32e-05	0.000796	CcSEcCtD
Amprenavir—Fatigue—Mitoxantrone—prostate cancer	8.26e-05	0.000789	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	8.25e-05	0.000789	CcSEcCtD
Amprenavir—Vomiting—Goserelin—prostate cancer	8.24e-05	0.000788	CcSEcCtD
Amprenavir—Discomfort—Etoposide—prostate cancer	8.21e-05	0.000785	CcSEcCtD
Amprenavir—Aspartate aminotransferase increased—Epirubicin—prostate cancer	8.18e-05	0.000782	CcSEcCtD
Amprenavir—Rash—Goserelin—prostate cancer	8.17e-05	0.000782	CcSEcCtD
Amprenavir—Dermatitis—Goserelin—prostate cancer	8.17e-05	0.000781	CcSEcCtD
Amprenavir—Vomiting—Conjugated Estrogens—prostate cancer	8.16e-05	0.000781	CcSEcCtD
Amprenavir—Mental disorder—Docetaxel—prostate cancer	8.16e-05	0.00078	CcSEcCtD
Amprenavir—Abdominal pain—Estradiol—prostate cancer	8.12e-05	0.000777	CcSEcCtD
Amprenavir—Headache—Goserelin—prostate cancer	8.12e-05	0.000777	CcSEcCtD
Amprenavir—Malnutrition—Docetaxel—prostate cancer	8.11e-05	0.000776	CcSEcCtD
Amprenavir—Rash—Conjugated Estrogens—prostate cancer	8.1e-05	0.000774	CcSEcCtD
Amprenavir—Dermatitis—Conjugated Estrogens—prostate cancer	8.09e-05	0.000773	CcSEcCtD
Amprenavir—Headache—Conjugated Estrogens—prostate cancer	8.04e-05	0.000769	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Epirubicin—prostate cancer	8.01e-05	0.000766	CcSEcCtD
Amprenavir—Mental disorder—Capecitabine—prostate cancer	7.9e-05	0.000756	CcSEcCtD
Amprenavir—Connective tissue disorder—Prednisone—prostate cancer	7.9e-05	0.000755	CcSEcCtD
Amprenavir—Malnutrition—Capecitabine—prostate cancer	7.85e-05	0.000751	CcSEcCtD
Amprenavir—Gastrointestinal pain—Mitoxantrone—prostate cancer	7.83e-05	0.000749	CcSEcCtD
Amprenavir—Liver function test abnormal—Doxorubicin—prostate cancer	7.76e-05	0.000742	CcSEcCtD
Amprenavir—Flatulence—Capecitabine—prostate cancer	7.74e-05	0.00074	CcSEcCtD
Amprenavir—Skin disorder—Etoposide—prostate cancer	7.74e-05	0.00074	CcSEcCtD
Amprenavir—Nausea—Goserelin—prostate cancer	7.7e-05	0.000736	CcSEcCtD
Amprenavir—Nausea—Conjugated Estrogens—prostate cancer	7.63e-05	0.000729	CcSEcCtD
Amprenavir—Anorexia—Etoposide—prostate cancer	7.59e-05	0.000726	CcSEcCtD
Amprenavir—Abdominal pain—Mitoxantrone—prostate cancer	7.57e-05	0.000724	CcSEcCtD
Amprenavir—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	7.57e-05	0.000724	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Doxorubicin—prostate cancer	7.41e-05	0.000709	CcSEcCtD
Amprenavir—Asthenia—Estradiol—prostate cancer	7.37e-05	0.000705	CcSEcCtD
Amprenavir—Tremor—Capecitabine—prostate cancer	7.36e-05	0.000703	CcSEcCtD
Amprenavir—Neutropenia—Epirubicin—prostate cancer	7.34e-05	0.000702	CcSEcCtD
Amprenavir—Pruritus—Estradiol—prostate cancer	7.27e-05	0.000695	CcSEcCtD
Amprenavir—Paraesthesia—Etoposide—prostate cancer	7.15e-05	0.000684	CcSEcCtD
Amprenavir—Hyperglycaemia—Epirubicin—prostate cancer	7.08e-05	0.000677	CcSEcCtD
Amprenavir—Mental disorder—Prednisone—prostate cancer	7.04e-05	0.000673	CcSEcCtD
Amprenavir—Diarrhoea—Estradiol—prostate cancer	7.03e-05	0.000672	CcSEcCtD
Amprenavir—Malnutrition—Prednisone—prostate cancer	7e-05	0.000669	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Epirubicin—prostate cancer	6.94e-05	0.000664	CcSEcCtD
Amprenavir—Decreased appetite—Etoposide—prostate cancer	6.92e-05	0.000662	CcSEcCtD
Amprenavir—Myalgia—Docetaxel—prostate cancer	6.91e-05	0.00066	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Etoposide—prostate cancer	6.88e-05	0.000658	CcSEcCtD
Amprenavir—Asthenia—Mitoxantrone—prostate cancer	6.87e-05	0.000657	CcSEcCtD
Amprenavir—Fatigue—Etoposide—prostate cancer	6.87e-05	0.000657	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	6.86e-05	0.000656	CcSEcCtD
Amprenavir—Neutropenia—Doxorubicin—prostate cancer	6.79e-05	0.00065	CcSEcCtD
Amprenavir—Myalgia—Capecitabine—prostate cancer	6.69e-05	0.000639	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	6.64e-05	0.000635	CcSEcCtD
Amprenavir—Hepatobiliary disease—Epirubicin—prostate cancer	6.62e-05	0.000633	CcSEcCtD
Amprenavir—Discomfort—Capecitabine—prostate cancer	6.61e-05	0.000632	CcSEcCtD
Amprenavir—Hyperglycaemia—Doxorubicin—prostate cancer	6.55e-05	0.000627	CcSEcCtD
Amprenavir—Diarrhoea—Mitoxantrone—prostate cancer	6.55e-05	0.000626	CcSEcCtD
Amprenavir—Vomiting—Estradiol—prostate cancer	6.53e-05	0.000625	CcSEcCtD
Amprenavir—Gastrointestinal pain—Etoposide—prostate cancer	6.51e-05	0.000623	CcSEcCtD
Amprenavir—Nervous system disorder—Docetaxel—prostate cancer	6.49e-05	0.000621	CcSEcCtD
Amprenavir—Rash—Estradiol—prostate cancer	6.48e-05	0.00062	CcSEcCtD
Amprenavir—Dermatitis—Estradiol—prostate cancer	6.47e-05	0.000619	CcSEcCtD
Amprenavir—Headache—Estradiol—prostate cancer	6.44e-05	0.000616	CcSEcCtD
Amprenavir—Skin disorder—Docetaxel—prostate cancer	6.43e-05	0.000615	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	6.42e-05	0.000614	CcSEcCtD
Amprenavir—Angioedema—Prednisone—prostate cancer	6.39e-05	0.000611	CcSEcCtD
Amprenavir—Anorexia—Docetaxel—prostate cancer	6.31e-05	0.000603	CcSEcCtD
Amprenavir—Abdominal pain—Etoposide—prostate cancer	6.3e-05	0.000602	CcSEcCtD
Amprenavir—Nervous system disorder—Capecitabine—prostate cancer	6.29e-05	0.000601	CcSEcCtD
Amprenavir—Skin disorder—Capecitabine—prostate cancer	6.23e-05	0.000595	CcSEcCtD
Amprenavir—ABCB1—lymph node—prostate cancer	6.2e-05	0.00743	CbGeAlD
Amprenavir—Connective tissue disorder—Epirubicin—prostate cancer	6.18e-05	0.00059	CcSEcCtD
Amprenavir—Hepatobiliary disease—Doxorubicin—prostate cancer	6.13e-05	0.000586	CcSEcCtD
Amprenavir—Anorexia—Capecitabine—prostate cancer	6.11e-05	0.000584	CcSEcCtD
Amprenavir—Nausea—Estradiol—prostate cancer	6.1e-05	0.000584	CcSEcCtD
Amprenavir—Vomiting—Mitoxantrone—prostate cancer	6.09e-05	0.000582	CcSEcCtD
Amprenavir—Rash—Mitoxantrone—prostate cancer	6.04e-05	0.000577	CcSEcCtD
Amprenavir—Dermatitis—Mitoxantrone—prostate cancer	6.03e-05	0.000577	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.03e-05	0.000577	CcSEcCtD
Amprenavir—Headache—Mitoxantrone—prostate cancer	6e-05	0.000574	CcSEcCtD
Amprenavir—Myalgia—Prednisone—prostate cancer	5.96e-05	0.000569	CcSEcCtD
Amprenavir—Paraesthesia—Docetaxel—prostate cancer	5.94e-05	0.000568	CcSEcCtD
Amprenavir—Erythema multiforme—Epirubicin—prostate cancer	5.94e-05	0.000568	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.91e-05	0.000565	CcSEcCtD
Amprenavir—Discomfort—Prednisone—prostate cancer	5.88e-05	0.000563	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.84e-05	0.000558	CcSEcCtD
Amprenavir—Cardiac disorder—Epirubicin—prostate cancer	5.83e-05	0.000558	CcSEcCtD
Amprenavir—Paraesthesia—Capecitabine—prostate cancer	5.76e-05	0.00055	CcSEcCtD
Amprenavir—Decreased appetite—Docetaxel—prostate cancer	5.75e-05	0.00055	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Docetaxel—prostate cancer	5.72e-05	0.000546	CcSEcCtD
Amprenavir—Asthenia—Etoposide—prostate cancer	5.72e-05	0.000546	CcSEcCtD
Amprenavir—Connective tissue disorder—Doxorubicin—prostate cancer	5.71e-05	0.000546	CcSEcCtD
Amprenavir—Fatigue—Docetaxel—prostate cancer	5.71e-05	0.000546	CcSEcCtD
Amprenavir—Nausea—Mitoxantrone—prostate cancer	5.69e-05	0.000544	CcSEcCtD
Amprenavir—Pruritus—Etoposide—prostate cancer	5.64e-05	0.000539	CcSEcCtD
Amprenavir—Nervous system disorder—Prednisone—prostate cancer	5.6e-05	0.000535	CcSEcCtD
Amprenavir—Decreased appetite—Capecitabine—prostate cancer	5.57e-05	0.000533	CcSEcCtD
Amprenavir—Skin disorder—Prednisone—prostate cancer	5.55e-05	0.00053	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Capecitabine—prostate cancer	5.53e-05	0.000529	CcSEcCtD
Amprenavir—Fatigue—Capecitabine—prostate cancer	5.53e-05	0.000528	CcSEcCtD
Amprenavir—Mental disorder—Epirubicin—prostate cancer	5.51e-05	0.000526	CcSEcCtD
Amprenavir—Erythema multiforme—Doxorubicin—prostate cancer	5.5e-05	0.000526	CcSEcCtD
Amprenavir—Malnutrition—Epirubicin—prostate cancer	5.47e-05	0.000523	CcSEcCtD
Amprenavir—Diarrhoea—Etoposide—prostate cancer	5.45e-05	0.000521	CcSEcCtD
Amprenavir—Anorexia—Prednisone—prostate cancer	5.44e-05	0.00052	CcSEcCtD
Amprenavir—Gastrointestinal pain—Docetaxel—prostate cancer	5.41e-05	0.000518	CcSEcCtD
Amprenavir—Cardiac disorder—Doxorubicin—prostate cancer	5.4e-05	0.000516	CcSEcCtD
Amprenavir—Flatulence—Epirubicin—prostate cancer	5.39e-05	0.000515	CcSEcCtD
Amprenavir—Gastrointestinal pain—Capecitabine—prostate cancer	5.24e-05	0.000501	CcSEcCtD
Amprenavir—Abdominal pain—Docetaxel—prostate cancer	5.23e-05	0.0005	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Prednisone—prostate cancer	5.2e-05	0.000497	CcSEcCtD
Amprenavir—Paraesthesia—Prednisone—prostate cancer	5.13e-05	0.00049	CcSEcCtD
Amprenavir—Mental disorder—Doxorubicin—prostate cancer	5.09e-05	0.000487	CcSEcCtD
Amprenavir—Abdominal pain—Capecitabine—prostate cancer	5.07e-05	0.000484	CcSEcCtD
Amprenavir—Vomiting—Etoposide—prostate cancer	5.06e-05	0.000484	CcSEcCtD
Amprenavir—Malnutrition—Doxorubicin—prostate cancer	5.06e-05	0.000484	CcSEcCtD
Amprenavir—Rash—Etoposide—prostate cancer	5.02e-05	0.00048	CcSEcCtD
Amprenavir—Dermatitis—Etoposide—prostate cancer	5.02e-05	0.00048	CcSEcCtD
Amprenavir—Headache—Etoposide—prostate cancer	4.99e-05	0.000477	CcSEcCtD
Amprenavir—Flatulence—Doxorubicin—prostate cancer	4.99e-05	0.000477	CcSEcCtD
Amprenavir—Decreased appetite—Prednisone—prostate cancer	4.96e-05	0.000474	CcSEcCtD
Amprenavir—Fatigue—Prednisone—prostate cancer	4.92e-05	0.000471	CcSEcCtD
Amprenavir—Asthenia—Docetaxel—prostate cancer	4.75e-05	0.000454	CcSEcCtD
Amprenavir—Nausea—Etoposide—prostate cancer	4.73e-05	0.000452	CcSEcCtD
Amprenavir—Pruritus—Docetaxel—prostate cancer	4.68e-05	0.000448	CcSEcCtD
Amprenavir—Gastrointestinal pain—Prednisone—prostate cancer	4.67e-05	0.000446	CcSEcCtD
Amprenavir—Myalgia—Epirubicin—prostate cancer	4.66e-05	0.000445	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.63e-05	0.000442	CcSEcCtD
Amprenavir—Discomfort—Epirubicin—prostate cancer	4.6e-05	0.00044	CcSEcCtD
Amprenavir—Asthenia—Capecitabine—prostate cancer	4.6e-05	0.00044	CcSEcCtD
Amprenavir—Pruritus—Capecitabine—prostate cancer	4.53e-05	0.000434	CcSEcCtD
Amprenavir—Diarrhoea—Docetaxel—prostate cancer	4.53e-05	0.000433	CcSEcCtD
Amprenavir—Abdominal pain—Prednisone—prostate cancer	4.51e-05	0.000431	CcSEcCtD
Amprenavir—Diarrhoea—Capecitabine—prostate cancer	4.39e-05	0.000419	CcSEcCtD
Amprenavir—Nervous system disorder—Epirubicin—prostate cancer	4.38e-05	0.000419	CcSEcCtD
Amprenavir—Skin disorder—Epirubicin—prostate cancer	4.34e-05	0.000415	CcSEcCtD
Amprenavir—Myalgia—Doxorubicin—prostate cancer	4.31e-05	0.000412	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.28e-05	0.000409	CcSEcCtD
Amprenavir—Discomfort—Doxorubicin—prostate cancer	4.26e-05	0.000407	CcSEcCtD
Amprenavir—Anorexia—Epirubicin—prostate cancer	4.26e-05	0.000407	CcSEcCtD
Amprenavir—Vomiting—Docetaxel—prostate cancer	4.21e-05	0.000402	CcSEcCtD
Amprenavir—Rash—Docetaxel—prostate cancer	4.17e-05	0.000399	CcSEcCtD
Amprenavir—Dermatitis—Docetaxel—prostate cancer	4.17e-05	0.000399	CcSEcCtD
Amprenavir—Headache—Docetaxel—prostate cancer	4.15e-05	0.000397	CcSEcCtD
Amprenavir—Asthenia—Prednisone—prostate cancer	4.1e-05	0.000392	CcSEcCtD
Amprenavir—Vomiting—Capecitabine—prostate cancer	4.08e-05	0.00039	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.07e-05	0.000389	CcSEcCtD
Amprenavir—Nervous system disorder—Doxorubicin—prostate cancer	4.05e-05	0.000387	CcSEcCtD
Amprenavir—Rash—Capecitabine—prostate cancer	4.04e-05	0.000386	CcSEcCtD
Amprenavir—Pruritus—Prednisone—prostate cancer	4.04e-05	0.000386	CcSEcCtD
Amprenavir—Dermatitis—Capecitabine—prostate cancer	4.04e-05	0.000386	CcSEcCtD
Amprenavir—Headache—Capecitabine—prostate cancer	4.02e-05	0.000384	CcSEcCtD
Amprenavir—Skin disorder—Doxorubicin—prostate cancer	4.01e-05	0.000384	CcSEcCtD
Amprenavir—Paraesthesia—Epirubicin—prostate cancer	4.01e-05	0.000383	CcSEcCtD
Amprenavir—Anorexia—Doxorubicin—prostate cancer	3.94e-05	0.000377	CcSEcCtD
Amprenavir—Nausea—Docetaxel—prostate cancer	3.93e-05	0.000376	CcSEcCtD
Amprenavir—Diarrhoea—Prednisone—prostate cancer	3.91e-05	0.000373	CcSEcCtD
Amprenavir—Decreased appetite—Epirubicin—prostate cancer	3.88e-05	0.000371	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Epirubicin—prostate cancer	3.85e-05	0.000369	CcSEcCtD
Amprenavir—Fatigue—Epirubicin—prostate cancer	3.85e-05	0.000368	CcSEcCtD
Amprenavir—Nausea—Capecitabine—prostate cancer	3.81e-05	0.000364	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.76e-05	0.00036	CcSEcCtD
Amprenavir—Paraesthesia—Doxorubicin—prostate cancer	3.71e-05	0.000355	CcSEcCtD
Amprenavir—Gastrointestinal pain—Epirubicin—prostate cancer	3.65e-05	0.000349	CcSEcCtD
Amprenavir—Vomiting—Prednisone—prostate cancer	3.63e-05	0.000347	CcSEcCtD
Amprenavir—Rash—Prednisone—prostate cancer	3.6e-05	0.000344	CcSEcCtD
Amprenavir—Dermatitis—Prednisone—prostate cancer	3.6e-05	0.000344	CcSEcCtD
Amprenavir—Decreased appetite—Doxorubicin—prostate cancer	3.59e-05	0.000343	CcSEcCtD
Amprenavir—Headache—Prednisone—prostate cancer	3.58e-05	0.000342	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.57e-05	0.000341	CcSEcCtD
Amprenavir—Fatigue—Doxorubicin—prostate cancer	3.56e-05	0.000341	CcSEcCtD
Amprenavir—Abdominal pain—Epirubicin—prostate cancer	3.53e-05	0.000337	CcSEcCtD
Amprenavir—Nausea—Prednisone—prostate cancer	3.39e-05	0.000324	CcSEcCtD
Amprenavir—Gastrointestinal pain—Doxorubicin—prostate cancer	3.38e-05	0.000323	CcSEcCtD
Amprenavir—Abdominal pain—Doxorubicin—prostate cancer	3.27e-05	0.000312	CcSEcCtD
Amprenavir—Asthenia—Epirubicin—prostate cancer	3.2e-05	0.000306	CcSEcCtD
Amprenavir—Pruritus—Epirubicin—prostate cancer	3.16e-05	0.000302	CcSEcCtD
Amprenavir—Diarrhoea—Epirubicin—prostate cancer	3.06e-05	0.000292	CcSEcCtD
Amprenavir—Asthenia—Doxorubicin—prostate cancer	2.96e-05	0.000283	CcSEcCtD
Amprenavir—Pruritus—Doxorubicin—prostate cancer	2.92e-05	0.000279	CcSEcCtD
Amprenavir—Vomiting—Epirubicin—prostate cancer	2.84e-05	0.000271	CcSEcCtD
Amprenavir—Diarrhoea—Doxorubicin—prostate cancer	2.83e-05	0.00027	CcSEcCtD
Amprenavir—Rash—Epirubicin—prostate cancer	2.82e-05	0.000269	CcSEcCtD
Amprenavir—Dermatitis—Epirubicin—prostate cancer	2.81e-05	0.000269	CcSEcCtD
Amprenavir—Headache—Epirubicin—prostate cancer	2.8e-05	0.000267	CcSEcCtD
Amprenavir—Nausea—Epirubicin—prostate cancer	2.65e-05	0.000254	CcSEcCtD
Amprenavir—Vomiting—Doxorubicin—prostate cancer	2.63e-05	0.000251	CcSEcCtD
Amprenavir—Rash—Doxorubicin—prostate cancer	2.6e-05	0.000249	CcSEcCtD
Amprenavir—Dermatitis—Doxorubicin—prostate cancer	2.6e-05	0.000249	CcSEcCtD
Amprenavir—Headache—Doxorubicin—prostate cancer	2.59e-05	0.000247	CcSEcCtD
Amprenavir—Nausea—Doxorubicin—prostate cancer	2.45e-05	0.000235	CcSEcCtD
Amprenavir—ABCC1—Disease—CTNNB1—prostate cancer	2.7e-06	3.25e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—SLC5A5—prostate cancer	2.69e-06	3.24e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GSTA1—prostate cancer	2.69e-06	3.24e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CYP1A1—prostate cancer	2.68e-06	3.22e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—COMT—prostate cancer	2.67e-06	3.22e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CYP1B1—prostate cancer	2.66e-06	3.21e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—GSTP1—prostate cancer	2.66e-06	3.2e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.66e-06	3.2e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GSTO1—prostate cancer	2.66e-06	3.2e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NAT2—prostate cancer	2.66e-06	3.2e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—ERCC2—prostate cancer	2.65e-06	3.2e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP2E1—prostate cancer	2.65e-06	3.19e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—GGT1—prostate cancer	2.64e-06	3.18e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CDKN1A—prostate cancer	2.63e-06	3.17e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—PTEN—prostate cancer	2.63e-06	3.17e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP2E1—prostate cancer	2.62e-06	3.16e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—NQO1—prostate cancer	2.62e-06	3.15e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—ITPR1—prostate cancer	2.62e-06	3.15e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—NCOA1—prostate cancer	2.6e-06	3.14e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—NQO1—prostate cancer	2.6e-06	3.13e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—TH—prostate cancer	2.58e-06	3.11e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—GGT1—prostate cancer	2.58e-06	3.11e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.57e-06	3.1e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CYP19A1—prostate cancer	2.57e-06	3.09e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—TH—prostate cancer	2.56e-06	3.08e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.55e-06	3.08e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—MTHFR—prostate cancer	2.55e-06	3.07e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—LRP2—prostate cancer	2.55e-06	3.07e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.55e-06	3.07e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PLCB2—prostate cancer	2.55e-06	3.07e-05	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—PIK3CB—prostate cancer	2.55e-06	3.07e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.54e-06	3.06e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—NCOA1—prostate cancer	2.54e-06	3.06e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP3A4—prostate cancer	2.53e-06	3.05e-05	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—PTGS2—prostate cancer	2.52e-06	3.04e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.52e-06	3.03e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.51e-06	3.02e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—EP300—prostate cancer	2.51e-06	3.02e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CYP19A1—prostate cancer	2.5e-06	3.02e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PPARA—prostate cancer	2.5e-06	3.02e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—P4HB—prostate cancer	2.5e-06	3.01e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—MTHFR—prostate cancer	2.49e-06	3.01e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.49e-06	3e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—RXRA—prostate cancer	2.48e-06	2.98e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—TYMS—prostate cancer	2.47e-06	2.98e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PPARA—prostate cancer	2.45e-06	2.95e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—GSTM1—prostate cancer	2.44e-06	2.95e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—SRC—prostate cancer	2.44e-06	2.94e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—GGT1—prostate cancer	2.43e-06	2.93e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.43e-06	2.93e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—RXRA—prostate cancer	2.42e-06	2.91e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—GGT1—prostate cancer	2.41e-06	2.9e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.41e-06	2.9e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—LPL—prostate cancer	2.4e-06	2.89e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—NCOA1—prostate cancer	2.39e-06	2.89e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—COMT—prostate cancer	2.39e-06	2.87e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—GSTP1—prostate cancer	2.37e-06	2.86e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—NCOA1—prostate cancer	2.37e-06	2.86e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.37e-06	2.85e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.36e-06	2.84e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CAV1—prostate cancer	2.35e-06	2.84e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—STAT3—prostate cancer	2.35e-06	2.83e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP19A1—prostate cancer	2.34e-06	2.82e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—ITPR1—prostate cancer	2.34e-06	2.81e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—MED12—prostate cancer	2.33e-06	2.81e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—COMT—prostate cancer	2.33e-06	2.81e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—GSTP1—prostate cancer	2.32e-06	2.79e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CYP1A1—prostate cancer	2.32e-06	2.79e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GNG5—prostate cancer	2.31e-06	2.78e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CAV1—prostate cancer	2.3e-06	2.77e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—ERCC2—prostate cancer	2.3e-06	2.77e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.3e-06	2.77e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—ITPR1—prostate cancer	2.28e-06	2.75e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—RXRA—prostate cancer	2.28e-06	2.74e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—RXRA—prostate cancer	2.26e-06	2.72e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NCOA3—prostate cancer	2.23e-06	2.68e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—TYMS—prostate cancer	2.21e-06	2.66e-05	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—PTEN—prostate cancer	2.2e-06	2.65e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.2e-06	2.65e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—COMT—prostate cancer	2.19e-06	2.64e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—MYC—prostate cancer	2.18e-06	2.63e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—GSTP1—prostate cancer	2.18e-06	2.63e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—GSTM1—prostate cancer	2.18e-06	2.63e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—TGFB1—prostate cancer	2.18e-06	2.62e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—COMT—prostate cancer	2.17e-06	2.62e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—GSTP1—prostate cancer	2.16e-06	2.61e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—MTHFR—prostate cancer	2.16e-06	2.6e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—TYMS—prostate cancer	2.15e-06	2.6e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—ITPR1—prostate cancer	2.15e-06	2.59e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PIK3CG—prostate cancer	2.14e-06	2.58e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—LPL—prostate cancer	2.14e-06	2.58e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—EGFR—prostate cancer	2.14e-06	2.57e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—ITPR1—prostate cancer	2.13e-06	2.57e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—GSTM1—prostate cancer	2.13e-06	2.57e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—HPGDS—prostate cancer	2.12e-06	2.56e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PPARA—prostate cancer	2.12e-06	2.55e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.11e-06	2.54e-05	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—EP300—prostate cancer	2.1e-06	2.53e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PIK3CG—prostate cancer	2.1e-06	2.52e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.09e-06	2.52e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—LPL—prostate cancer	2.09e-06	2.52e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CYP1A1—prostate cancer	2.07e-06	2.49e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—ACHE—prostate cancer	2.06e-06	2.48e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GSTT1—prostate cancer	2.06e-06	2.48e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—ERCC2—prostate cancer	2.05e-06	2.47e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.04e-06	2.45e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—TYMS—prostate cancer	2.03e-06	2.45e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—INS—prostate cancer	2.03e-06	2.45e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CYP1A1—prostate cancer	2.02e-06	2.43e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—KRAS—prostate cancer	2.02e-06	2.43e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—TYMS—prostate cancer	2.01e-06	2.42e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—GSTM1—prostate cancer	2.01e-06	2.42e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—ERCC2—prostate cancer	2e-06	2.41e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CAV1—prostate cancer	1.99e-06	2.4e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—GSTM1—prostate cancer	1.99e-06	2.4e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CREBBP—prostate cancer	1.99e-06	2.39e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—INS—prostate cancer	1.98e-06	2.39e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.98e-06	2.39e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PRKACB—prostate cancer	1.97e-06	2.37e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—LPL—prostate cancer	1.97e-06	2.37e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—LPL—prostate cancer	1.95e-06	2.35e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.95e-06	2.35e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CREBBP—prostate cancer	1.94e-06	2.34e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—MTHFR—prostate cancer	1.93e-06	2.32e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.9e-06	2.29e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.9e-06	2.29e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PPARA—prostate cancer	1.89e-06	2.28e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—ERCC2—prostate cancer	1.89e-06	2.27e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.89e-06	2.27e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PIK3CD—prostate cancer	1.88e-06	2.27e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—MTHFR—prostate cancer	1.88e-06	2.27e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—ERCC2—prostate cancer	1.87e-06	2.25e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NCOA2—prostate cancer	1.86e-06	2.24e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—PIK3CA—prostate cancer	1.85e-06	2.23e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PPARA—prostate cancer	1.85e-06	2.22e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.84e-06	2.22e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.81e-06	2.19e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—NOS3—prostate cancer	1.78e-06	2.14e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CAV1—prostate cancer	1.78e-06	2.14e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—MTHFR—prostate cancer	1.77e-06	2.14e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.77e-06	2.14e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—MTHFR—prostate cancer	1.76e-06	2.12e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PPARA—prostate cancer	1.74e-06	2.1e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—NOS3—prostate cancer	1.74e-06	2.1e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CAV1—prostate cancer	1.74e-06	2.09e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.73e-06	2.09e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PPARA—prostate cancer	1.72e-06	2.08e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—INS—prostate cancer	1.72e-06	2.07e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NQO1—prostate cancer	1.71e-06	2.06e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.7e-06	2.05e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—TH—prostate cancer	1.69e-06	2.03e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CREBBP—prostate cancer	1.68e-06	2.03e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PIK3CB—prostate cancer	1.64e-06	1.98e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—IL6—prostate cancer	1.64e-06	1.98e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.64e-06	1.98e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CAV1—prostate cancer	1.64e-06	1.97e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PTGS2—prostate cancer	1.63e-06	1.96e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CAV1—prostate cancer	1.62e-06	1.95e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.62e-06	1.95e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.61e-06	1.93e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.6e-06	1.92e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PTGS2—prostate cancer	1.59e-06	1.92e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GGT1—prostate cancer	1.59e-06	1.92e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PIK3CG—prostate cancer	1.58e-06	1.91e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NCOA1—prostate cancer	1.57e-06	1.89e-05	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—PIK3CA—prostate cancer	1.55e-06	1.87e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.55e-06	1.87e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.54e-06	1.86e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—INS—prostate cancer	1.53e-06	1.85e-05	CbGpPWpGaD
Amprenavir—ABCC1—Disease—AKT1—prostate cancer	1.51e-06	1.82e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—NOS3—prostate cancer	1.51e-06	1.82e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CREBBP—prostate cancer	1.5e-06	1.81e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—INS—prostate cancer	1.5e-06	1.8e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.49e-06	1.8e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—RXRA—prostate cancer	1.49e-06	1.79e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.48e-06	1.78e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CREBBP—prostate cancer	1.47e-06	1.77e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—COMT—prostate cancer	1.43e-06	1.73e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GSTP1—prostate cancer	1.43e-06	1.72e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.42e-06	1.72e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PTEN—prostate cancer	1.42e-06	1.71e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—INS—prostate cancer	1.41e-06	1.7e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—ITPR1—prostate cancer	1.4e-06	1.69e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—INS—prostate cancer	1.4e-06	1.68e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.39e-06	1.68e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PIK3CD—prostate cancer	1.39e-06	1.67e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PTEN—prostate cancer	1.39e-06	1.67e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CREBBP—prostate cancer	1.38e-06	1.66e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PTGS2—prostate cancer	1.38e-06	1.66e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CREBBP—prostate cancer	1.37e-06	1.65e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—EP300—prostate cancer	1.35e-06	1.63e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—NOS3—prostate cancer	1.34e-06	1.62e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—TYMS—prostate cancer	1.33e-06	1.6e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—EP300—prostate cancer	1.32e-06	1.59e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—NOS3—prostate cancer	1.31e-06	1.58e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—GSTM1—prostate cancer	1.31e-06	1.58e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.31e-06	1.58e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.3e-06	1.56e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—LPL—prostate cancer	1.29e-06	1.55e-05	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—AKT1—prostate cancer	1.27e-06	1.53e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.24e-06	1.5e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.24e-06	1.5e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—NOS3—prostate cancer	1.24e-06	1.49e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—ERCC2—prostate cancer	1.23e-06	1.49e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PTGS2—prostate cancer	1.23e-06	1.48e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—NOS3—prostate cancer	1.23e-06	1.48e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PIK3CB—prostate cancer	1.21e-06	1.46e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PTEN—prostate cancer	1.2e-06	1.45e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PTGS2—prostate cancer	1.2e-06	1.45e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—MTHFR—prostate cancer	1.16e-06	1.4e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—EP300—prostate cancer	1.15e-06	1.38e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.14e-06	1.38e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PPARA—prostate cancer	1.14e-06	1.37e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.13e-06	1.36e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PTGS2—prostate cancer	1.13e-06	1.36e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PTGS2—prostate cancer	1.12e-06	1.35e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PTEN—prostate cancer	1.07e-06	1.29e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CAV1—prostate cancer	1.07e-06	1.29e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PTEN—prostate cancer	1.05e-06	1.26e-05	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—EP300—prostate cancer	1.02e-06	1.23e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PIK3CA—prostate cancer	1e-06	1.21e-05	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—EP300—prostate cancer	9.98e-07	1.2e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PTEN—prostate cancer	9.87e-07	1.19e-05	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PIK3CA—prostate cancer	9.79e-07	1.18e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PTEN—prostate cancer	9.78e-07	1.18e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PIK3CG—prostate cancer	9.74e-07	1.17e-05	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—EP300—prostate cancer	9.41e-07	1.13e-05	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—EP300—prostate cancer	9.33e-07	1.12e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—INS—prostate cancer	9.22e-07	1.11e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CREBBP—prostate cancer	9.03e-07	1.09e-05	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PIK3CD—prostate cancer	8.56e-07	1.03e-05	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PIK3CA—prostate cancer	8.48e-07	1.02e-05	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—AKT1—prostate cancer	8.18e-07	9.86e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NOS3—prostate cancer	8.09e-07	9.74e-06	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—AKT1—prostate cancer	8e-07	9.63e-06	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PIK3CA—prostate cancer	7.57e-07	9.12e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PIK3CB—prostate cancer	7.46e-07	8.99e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PTGS2—prostate cancer	7.4e-07	8.91e-06	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PIK3CA—prostate cancer	7.39e-07	8.9e-06	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PIK3CA—prostate cancer	6.96e-07	8.39e-06	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—AKT1—prostate cancer	6.93e-07	8.34e-06	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PIK3CA—prostate cancer	6.9e-07	8.31e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PTEN—prostate cancer	6.45e-07	7.77e-06	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—AKT1—prostate cancer	6.18e-07	7.45e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—EP300—prostate cancer	6.15e-07	7.41e-06	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—AKT1—prostate cancer	6.03e-07	7.27e-06	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—AKT1—prostate cancer	5.69e-07	6.85e-06	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—AKT1—prostate cancer	5.64e-07	6.79e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.55e-07	5.48e-06	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—AKT1—prostate cancer	3.72e-07	4.48e-06	CbGpPWpGaD
